Lilly weight-loss pill orforglipron could get FDA approval in 2026, CEO Dave Ricks says

Eli Lilly & Co., the Fortune 500 pharma firm that makes weight-loss injection Zepbound (tirzepatide), has a comparable oral drug in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks spoke to Bloomberg TV on January 13, 2025.

Gam1983/Getty Images